The average P/S ratio for CRNX's competitors is 58.55, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of 261.07, which is 345.91% above the industry average. Given its robust revenue growth of -43.59%, this premium appears unsustainable.